Oncopeptides AB (publ) ONCO

Updated: 8 Aug 2026

Stockholm | Biotech | Biotechnology

No signal published yet

We already track Oncopeptides and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Oncopeptides free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
Stockholm
Type
Biotech
Sector
Biotechnology
We're already tracking Oncopeptides AB (publ) — here are the latest events we've registered

Recent News

  • On June 12, 2026, Oncopeptides submitted a Type II variation application to the European Medicines Agency to expand Pepaxti's indication to third-line treatment for multiple myeloma. The official regulatory review procedure commenced on June 20, 2026, following validation by the EMA.

What Firelda Watch includes for Oncopeptides AB (publ)

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Oncopeptides AB (publ) will be delivered in the same format.

Sample analyses in the same sector

Sample full analysis — same format your watchlist gets

Hansa Biopharma AB (publ)
HNSA
HOLD
Bioarctic
BIOA B
BUY
Sprint Bioscience AB (publ)
SPRINT
NEUTRAL
Xbrane Biopharma AB (publ)
XBRANE
HOLD
SynAct Pharma AB
SYNACT
HOLD

Biotech

More companies in this sector

Want to follow Oncopeptides AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Oncopeptides free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Oncopeptides AB (publ) ONCO
Oncopeptides — follow and we'll monitor it
Follow Oncopeptides free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.